Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial.
S. Hegewisch-Becker
Consultant or Advisory Role - Merck; Roche
C. A. Lerchenmuller
No relevant relationships to disclose
A. Welt
Consultant or Advisory Role - Amgen; AstraZeneca; Essex Pharma; Fresenius Biotech
Honoraria - Pfizer; Pierre Fabre Medicament; Roche
T. Decker
No relevant relationships to disclose
M. Just
No relevant relationships to disclose
C. Steffens
No relevant relationships to disclose
A. Hipper
No relevant relationships to disclose
N. Marschner
Honoraria - Roche